AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study is looking at a new drug called AZD4547 which is being tested for the treatment of
oestrogen receptor positive breast cancer. AZD4547 is a drug which specifically "blocks"
proteins called fibroblast growth factor receptors (FGFR1) that are involved in the processes
that help cancer cells to grow. These proteins may also be responsible for the development of
resistance to hormonal therapies used to treat some breast cancers. AZD4547 is not yet
approved for use in breast cancer and is therefore being used in this study as a research
drug.
The investigators will also test the theory that it is not necessary for high levels of FGFR1
to be present in the body to see benefit from AZD4547. (Stage 1 only)